Abstract:Background: Programmed cell death protein 1 (PD-1) receptor has two ligands,programmed death-ligand 1 (PD-L1) and PD-L2. When compared with PD-L1, PD-L2 has not received much attention, and its role remains unclear. Methods: The expression profiles of pdcd1lg2 (PD-L2-encoding gene) mRNA and PD-L2 protein were analyzed using TCGA, ICGC, and HPA databases. Kaplan-Meier and Cox regression analyses were used to assess the prognostic significance of PD-L2. We used GSEA, Spearman's correlation analysis and PPI network to explore the biological functions of PD-L2. PD-L2-associated immune cell infiltration was evaluated using the ESTIMATE algorithm and TIMER 2.0. The expressions of PD-L2 in tumor-associated macrophages (TAMs) in human colon cancer samples, and in mice in an immunocompetent syngeneic setting were verified using scRNA-seq datasets, multiplex immunofluorescence staining, and flow cytometry. After fluorescence-activated cell sorting, flow cytometry and qRT-PCR and transwell and colony formation assays were used to evaluate the phenotype and functions of PD-L2+TAMs. Immune checkpoint inhibitors (ICIs) therapy prediction analysis was performed using TIDE and TISMO. Last, a series of targeted small-molecule drugs with promising therapeutic effects were predicted using the GSCA platform. Results: PD-L2 was expressed in all the common human cancer types and deteriorated outcomes in multiple cancers. PPI network and Spearman's correlation analysis revealed that PD-L2 was closely associated with many immune molecules. Moreover, both GSEA results of KEGG pathways and GSEA results for Reactome analysis indicated that PD-L2 expression played an important role in cancer immune response. Further analysis showed that PD-L2 expression was strongly associated with the infiltration of immune cells in tumor tissue in almost all cancer types, among which macrophages were the most positively associated with PD-L2 in colon cancer. According to the results mentioned above, we verified the expression of PD-L2 in TAMs in colon cancer and found that PD-L2+TAMs population was not static. Additionally, PD-L2+TAMs exhibited protumor M2 phenotype and increased the migration, invasion, and proliferative capacity of colon cancer cells. Furthermore, PD-L2 had a substantial predictive value for ICIs therapy cohorts. Conclusion: PD-L2 in the TME, especially expressed on TAMs, could be applied as a potential therapeutic target.

PD-L1 Interacts with Frizzled 6 to Activate Β-Catenin and Form a Positive Feedback Loop to Promote Cancer Stem Cell Expansion

PD-L1-expressing B cells promote murine breast cancer development and mediate response to anti-PD-L1 immune checkpoint inhibitor.

Constitutive Expression Of Wnt/Beta-Catenin Target Genes Promotes Proliferation And Invasion Of Liver Cancer Stem Cells

PD-L1 (B7-H1) Competes with the RNA Exosome to Regulate the DNA Damage Response and Can Be Targeted to Sensitize to Radiation or Chemotherapy.

Wnt5b-induced PCP/JNK Activation Promotes PD-L1 Expression and the Malignant Phenotype of Non-small Cell Lung Cancer

PD-1 and its ligands are important immune checkpoints in cancer

PD‐L1 regulates epithelial–mesenchymal transition and cancer stem cell phenotypes in Hepatocellular Carcinoma through SGK2/β‐catenin signaling pathway

Cancer‐associated Fibroblasts Promote PD‐L1 Expression in Mice Cancer Cells Via Secreting CXCL5

PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC

Cancer-Associated Fibroblasts Promote the Upregulation of PD-L1 Expression Through Akt Phosphorylation in Colorectal Cancer

Beta-Catenin Induces Transcriptional Expression Of Pd-L1 To Promote Glioblastoma Immune Evasion

Pd-L1 Promotes Tumor Growth And Progression By Activating Wip And Beta-Catenin Signaling Pathways And Predicts Poor Prognosis In Lung Cancer

PD‑L1 promotes head and neck squamous cell carcinoma cell growth through mTOR signaling.

Pan-cancer analysis identifies PD-L2 as a tumor promotor in the tumor microenvironment

PD-L1 promotes tumor growth and progression by activating WIP and β-catenin signaling pathways and predicts poor prognosis in lung cancer

PD-1/PD-L1 interaction up-regulates MDR1/P-gp expression in breast cancer cells via PI3K/AKT and MAPK/ERK pathways

Programmed death ligand 1 promotes lymph node metastasis and glucose metabolism in cervical cancer by activating integrin β4/SNAI1/SIRT3 signaling pathway

Cancer Cell-Intrinsic PD-1 and Implications in Combinatorial Immunotherapy.

Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type

Cancer cell-intrinsic PD-1: Its role in malignant progression and immunotherapy

PD-L1 Deficiency Sensitizes Tumor Cells to DNA-PK Inhibition and Enhances Cgas-Sting Activation.